Dreamm-2: single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma (rrmm), including subgroups with renal impairment (ri) and high-risk (hr) cytogenetics

Dreamm-2: single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma (rrmm), including subgroups with renal impairment (ri) and high-risk (hr) cytogenetics

Introduction: Belanatamab mafodotin (GSK2857916; belamaf; BLENREP) showed deep and durable single-agent activity in the pivotal DREAMM-2 study primary analysis (NCT03525678)(1–5) in a patient population that historically has a poor prognosis (overall survival [OS] 6–9 months). This study aims to pr...

Full description

Bibliographic Details
Main Authors: S. Lonial, H.C. Lee, A. Badros, S. Trudel, A.K. Nooka, A. Chari, A-O. Abdallah, N.S. Callander, D.W. Sborov, A. Suvannasankha, K. Weisel, P.M. Voorhees, M. Hultcrantz, E.N. Libby, P.G. Richardson, P. Rodriguez Otero, B. Besemer, T. Facon, A. Hoos, J. Baron, T. Piontek, R.C. Jewell, E. Lewis, J. Opalinska, I. Gupta, A.D. Cohen, A. Medaglia
Format: Article
Language:English
Published: PAGEPress Publications 2020-09-01
Series:Hematology Reports
Online Access:https://www.pagepress.org/journals/index.php/hr/article/view/8916

Internet

https://www.pagepress.org/journals/index.php/hr/article/view/8916

Similar Items